The grant supports efforts around the preclinical discovery phase of analysis. Patients who suffer from Duchenne muscular dystrophy cannot develop a protein vital for strength-building, and gradually suffer from muscle deterioration. The stem cell treatment can be used to replace the diseased muscle tissue with healthy muscle. It also creates healthy myofibers that create proteins.
If the preclinical phase is successful, researchers will begin a phase 1 study.
More articles on biologics:
NASS unveils ’20 Under 40′ spine surgeons for 2019
Dr. Death to hit TV screens: A timeline of the former neurosurgeon’s case
How spine, neurosurgery departments are evolving — key thoughts from 4 leaders
